VISTAGEN THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net of -$4.90 million for the 9-month period ending 2015-12-31, per its 10-Q filed 2016-02-16.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet · last filed 2016-02-16
- VISTAGEN THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for the quarter ending 2015-12-31 was $0.00.
- VISTAGEN THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for the quarter ending 2015-09-30 was $0.00.
- VISTAGEN THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for the quarter ending 2015-06-30 was -$4.90M.
- VISTAGEN THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for fiscal 2013 was $1.69M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-02-16 | $0.00 derived: sum of 2 quarters · filed 2016-02-16 | -$4.90M 10-Q · filed 2016-02-16 | |
| 2015-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-11-16 | -$4.90M 10-Q · filed 2015-11-16 | ||
| 2015-06-30 | -$4.90M 10-Q · filed 2015-08-14 | |||
| 2013-03-31 | $1.69M 10-K · filed 2014-06-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |